文献速递自身炎症与 IgG4 相关病

家族性地中海热与秋水仙碱的肝脏风险:倾向评分匹配分析

Disentangling the hepatic risks of familial Mediterranean Fever and colchicine: A propensity score-matched analysis of 19,231 patients.
PubMed 文献 · Semin Arthritis Rheum · 2026-07-28

这项回顾性队列研究纳入以色列三级医疗中心19,231例患者,采用倾向评分匹配和多因素logistic回归,评估家族性地中海热(FMF)诊断与秋水仙碱治疗对肝硬化和脂肪肝的独立关联。结果发现FMF诊断与肝硬化(OR=4.00;95%CI:2.78-5.75)和脂肪肝(OR=2.03;95%CI:1.57-2.61)风险升高显著相关,而秋水仙碱治疗与两种肝病风险均无显著关联。结论提示FMF本身而非秋水仙碱与肝脏损伤风险增加独立相关。

要点

  • FMF诊断与肝硬化风险升高独立相关(OR=4.00;95%CI:2.78-5.75)。
  • FMF诊断与脂肪肝风险升高独立相关(OR=2.03;95%CI:1.57-2.61)。
  • 秋水仙碱治疗未显示与肝硬化或脂肪肝风险升高相关。

核心结论

  • FMF诊断与肝硬化及脂肪肝风险增加独立相关,而秋水仙碱治疗未显示额外肝脏毒性。
  • 控制FMF相关炎症对预防肝脏并发症具有重要意义,并支持继续使用秋水仙碱作为安全治疗药物。

研究设计与样本

  • 回顾性队列研究,利用以色列一家三级医疗中心的电子病历数据。
  • 纳入诊断为FMF、痛风、假性痛风或心包炎的患者,共19,231例。
  • 采用倾向评分匹配分离FMF诊断与秋水仙碱治疗效应,并构建多因素logistic回归模型校正混杂因素。

主要发现

  • FMF诊断与肝硬化风险升高显著相关(OR=4.00;95%CI:2.78-5.75),在匹配与未匹配队列中均一致。
  • FMF诊断与脂肪肝风险升高显著相关(OR=2.03;95%CI:1.57-2.61),在匹配与未匹配队列中均一致。
  • 秋水仙碱治疗与肝硬化风险无显著关联(OR=0.92;95%CI:0.69-1.22)。
  • 秋水仙碱治疗与脂肪肝风险无显著关联(OR=1.01;95%CI:0.85-1.21)。

临床怎么用

  • 对FMF患者应重视控制疾病相关炎症,以降低肝硬化与脂肪肝风险。
  • 秋水仙碱长期治疗在该人群中未显示额外肝脏毒性,支持继续安全使用。

局限性

  • 本研究为单中心回顾性队列研究,基于电子病历与ICD编码、影像及活检数据判定肝脏结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disease commonly treated with lifelong colchicine therapy. Although colchicine is considered safe, its long-term hepatic effects remain debated. Distinguishing liver injury attributable to FMF itself from that induced by colchicine is essential for guiding clinical management. OBJECTIVES: To determine whether FMF or colchicine exposure are independently associated with liver cirrhosis and fatty liver disease. METHODS: This retrospective cohort study utilized electronic medical records from a tertiary care centre in Israel. Patients diagnosed with FMF, gout, pseudogout, or pericarditis were included. Liver injury outcomes were assessed via ICD codes, imaging, and biopsy data. Propensity score matching was applied to isolate the effects of FMF diagnosis and colchicine treatment, and multivariate logistic regression models were constructed to adjust for relevant confounders. RESULTS: Among 19,231 patients, FMF diagnosis was significantly associated with increased risk of cirrhosis (OR = 4.00; 95% CI: 2.78-5.75) and fatty liver (OR = 2.03; 95% CI: 1.57-2.61), both in unmatched and matched cohorts. In contrast, colchicine treatment was not associated with elevated OR for either condition (Cirrhosis OR = 0.92 [95% CI: 0.69-1.22]; Fatty Liver OR = 1.01 [95% CI: 0.85-1.21]). CONCLUSIONS: FMF is independently associated with increased hepatic injury risk, while colchicine treatment does not appear to confer additional liver toxicity. These findings underscore the importance of controlling FMF-related inflammation to prevent hepatic complications, and support the continued use of colchicine as a safe therapeutic agent in this population.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Gilad-Dor L, Lidar M, Ben-Zvi I, et al. Disentangling the hepatic risks of familial Mediterranean Fever and colchicine: A propensity score-matched analysis of 19,231 patients. Semin Arthritis Rheum. 2026. PMID: 42561765. doi:10.1016/j.semarthrit.2026.153045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。